Ionis Pharmaceuticals Stock Outlook and Analyst Ratings
No Comments on Ionis Pharmaceuticals Stock Outlook and Analyst Ratings
Ionis Pharmaceuticals has maintained a Moderate Buy rating from analysts. We dive into the company's clinical pipeline, the potential of its RNA-targeted technology, and what investors should consider before making a move.